CASE REPORT

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab

Ayumu Takahashi, Akihito Kubo, Shohei Mizuno, Kenji Kasai, Nobuhiro Asai, Toshiyuki Yonezawa, Kenshi Kosaka, Masaki Nishimura, Hiroyuki Tanaka, Norihiro Yokoe, Toyonori Tsuzuki, Akiyoshi Takami and Etsuro Yamaguchi

Abstract:
A 73-year-old man who was a current smoker complained of weakness in his limbs and slow movement and was diagnosed with primary lung melanoma with brain metastases. Following stereotactic brain radiotherapy, nivolumab was administrated. After the first cycle of nivolumab, his blood neutrophil count and hemoglobin levels started to decline. Excluding other possible causes, nivolumab was considered the most probable cause of bicytopenia. Nivolumab was not restarted, and the bicytopenia gradually recovered with no corticosteroid administration for this event. While serious hematological adverse events regarding immune checkpoint inhibitors have been assumed to be rare, severe neutropenia and anemia should be considered in patients receiving immune checkpoint therapy.

Key words: immune checkpoint inhibitor, nivolumab, neutropenia, anemia, hematological adverse event

(Intern Med 58: 827-831, 2019)
(DOI: 10.2169/internalmedicine.1011-18)

Introduction

Immune checkpoint inhibitors are emerging therapeutic agents for various types of tumors that restore the antitumor immune response suppressed during tumor progression (1-3). Monoclonal antibodies targeting programmed cell death (PD)-1 or PD-ligand 1 (PD-L1) have outperformed, with milder toxicities, conventional cytotoxic chemotherapies in clinical trials of solid tumors, including non-small cell lung cancer (NSCLC). It has been assumed that immune checkpoint therapy less frequently induces hematological adverse events than cytotoxic chemotherapy because of its mechanism of action. Indeed, clinical studies of immune checkpoint inhibitors have shown that hematological adverse events are rare, especially severe adverse events (4-7). Nivolumab is the first approved immune checkpoint inhibitor antibody targeting PD-1 and was approved for melanoma, followed by NSCLC.

We herein report a rare case of severe neutropenia and anemia after nivolumab therapy in a patient with primary lung melanoma.

Case Report

A 73-year-old man who was a current smoker consulted Aichi Medical University Hospital in December 2015 complaining of weakness in his limbs and slow movement. Brain magnetic resonance imaging showed three enhanced lesions (Fig. 1A and B). Chest X-ray and computed tomography showed a 35-mm mass in the lower lobe of the right lung (Fig. 1C and D). A transbronchial biopsy specimen of the right lung tumor revealed atypical cells positive for S-100 and melanoma-associated antigen HMB-45 (Fig. 2) and negative for thyroid transcription factor-1, Napsin A, p 40, and pan-cytokeratin AE1/AE3, suggesting melanoma. There were no skin or gut lesions indicative of melanoma. A final diagnosis of primary lung melanoma...
Figure 1. Brain magnetic resonance imaging (MRI), chest X-ray and computed tomography (CT) findings at the first visit. Brain MRI showed an enhanced 25-mm nodule in the right frontal lobe, a 31-mm mass in the left temporal lobe and a 15-mm nodule in the left putamen (A, B). Chest X-ray and CT showed a 35-mm mass in the lower lobe of the right lung (C, D).

with brain metastases was reached, and stereotactic brain radiotherapy was performed.

Nivolumab (3 mg/kg) therapy was started in February 2016. After nivolumab administration, his blood neutrophil count and hemoglobin (Hb) levels started to decline (Fig. 3). The nadir neutrophil count at day 16 of nivolumab administration was 456/μL and increased without granulocyte colony-stimulating factor injection. Thirty days after the administration, Hb dropped to 7.1 g/dL with a blood reticulocyte count in the normal range (5%). Serum ferritin (882.4 ng/mL), iron (335 mg/dL) and haptoglobin (type 2-2, 97 mg/dL) levels did not decrease, and the serum bilirubin (0.64 mg/dL) level was not high. Upper gastrointestinal tract endoscopy showed no bleeding lesions, and no apparent tarry or bloody feces were observed. Bone marrow aspiration resulted in dry-tap. A bone marrow biopsy showed hypoplasia of hematopoietic cells and no tumor cell infiltration (Fig. 4). With regard to drug-induced hematological disorders, the patient had been regularly taking dexamethasone for brain edema along with trimethoprim-sulfamethoxazole, vitamin K and proton pump inhibitors to prevent adverse effects from corticosteroids since December 2015. Dexamethasone had been started at 3.3 mg/day and was gradually tapered to 2 mg/day 3 weeks before nivolumab administration. Trimethoprim-sulfamethoxazole, vitamin K and proton pump inhibitors were also continued with no dose modifications. The patient received red blood cell transfusions 30 and 34 days after nivolumab administration. Thirty-seven days after administration, the Hb level and reticulocyte count rose to 9.0 g/dL and 29%, respectively, and anemia gradually improved.

Nivolumab was not restarted, and the tumor remained in a stable disease status for six months until disease progression. After disease progression, the patient declined any active treatment and died of primary lung melanoma nine months after starting nivolumab administration.

Discussion

In the present case, neutropenia and anemia progressed after a single nivolumab administration. Considering his stable use of medications except for nivolumab, we speculated that drug-induced bicytopenia independent of nivolumab was unlikely. Excluding other possible causes of simultaneous anemia and neutropenia, nivolumab was considered the most probable cause of bicytopenia. Bone marrow findings and peripheral blood results suggested hematopoietic hypoplasia. Although the precise mechanism remained unclear, a nivolumab-induced immune related anaplastic mechanism might have been involved.
Clinical studies for NSCLC have shown that hematological adverse events from nivolumab are less frequent than with cytotoxic chemotherapies. The frequency of anemia was 2-3% for any grade and <1% for grades 3 and 4 (4-6). Furthermore, the frequency of neutropenia was <1% (4-6), and that of thrombocytopenia 1% (6) for any grade. Studies of nivolumab for urothelial carcinoma (7) and mucosal melanoma (8) have shown that anemia was more frequent
(10% and 3.5%, respectively) than that in the studies for NSCLC, while the rate of severe anemia was 0% in both studies. In studies of pembrolizumab (9) and tremelimumab (10), other immune checkpoint inhibitors, the rate of severe hematological adverse events was less than 2%.

Several case reports have described nivolumab-induced blood cell reduction (11-16), including a case with bicytopenia (15, 16). In those reports, cases of autoimmune hemolytic anemia (13, 14) and autoimmune neutropenia (16) were described. Hematological adverse events induced by ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4, were also reported, with red blood cell aplasia described (17, 18). In those reports, an immune related mechanism was assumed, and corticosteroids were administrated to treat hematological disorders. Unlike previous reports, both neutropenia and anemia in our present case progressed relatively slowly and recovered over a short period of time with no additional corticosteroid administration, despite the severity of his bicytopenia. The patient had no symptoms due to bicytopenia. He continuously received low-dose dexamethasone for brain edema. This might have some effect on the course of bicytopenia. In such a case, additional corticosteroids might not necessarily be needed.

**Conclusion**

Although severe hematological adverse events are rare when immune checkpoint inhibitors are used, severe neutropenia and anemia should be considered when encountering such cases.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348: 56-61, 2015.
2. Medina PJ, Adams VR. PD-1 Pathway inhibitors: immunoncology agents for restoring antitumor immune responses. Pharmacotherapy 36: 317-334, 2016.
3. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 11: 1307-1326, 2015.
4. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015.
5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.
6. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376: 2415-2426, 2017.
7. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase I/II trial. Lancet Oncol 17: 1590-1598, 2016.
8. D’Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35: 226-235, 2017.
9. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.
10. Ribas A, Kefferd R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616-622, 2013.
11. Turgeman I, Wollner M, Hassoun G, et al. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anticancer Drugs 28: 811-814, 2017.
12. Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer 99: 123-126, 2016.
13. Schwab KS, Heine A, Weimann T, et al. Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia. Case Rep Oncol 9: 373-378, 2016.
14. Palla AR, Kennedy D, Moshaiffah H, et al. Autoimmune hemolytic anemia as a complication of nivolumab therapy. Case Rep Oncol 9: 691-697, 2016.
15. Inadomi K, Kugai H, Arita S, et al. Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: a case report. Medicine (Baltimore) 95: e4283, 2016.
16. Bulbul A, Mustafa A, Chouial S, et al. Idiopathic thrombocy-
topenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin’s lymphoma. Ann Oncol 28: 1675-1676, 2017.

17. Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med 374: 1096-1097, 2016.

18. Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58: 1351-1353, 2009.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).